PRAX FDA calendar & decision history Praxis Precision Medicines Inc. · 2 upcoming · 0 past FDA decisions
Upcoming FDA catalysts PRAX · Dec 27, 2026 Relutrigine (PRAX-562) - (EMBOLD) — Developmental epileptic encephalopathies (DEEs) PRAX · Jan 29, 2027 ulixacaltamide See the full 2026 PDUFA calendar → This page aggregates PRAX's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio